ALUPENT LIQ 50MG/ML DIN 00003859
Status: Cancelled Post Market
Holder: BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Molecule: ORCIPRENALINE SULFATE
Health Canada record
| Active ingredient(s) | ORCIPRENALINE SULFATE 50 MG |
|---|---|
| Dosage form | Liquid |
| Route | Inhalation; Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | R03AB03 ORCIPRENALINE |
| Original market date | 31-Dec-1970 |
| Current status date | 14-Aug-1997 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ORCIPRENALINE SULFATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02236565 | ORCIPRENALINE | APOTEX INC | Syrup | ORCIPRENALINE SULFATE 2 MG | Approved |
| 00249920 | ALUPENT SYR 10MG/5.0ML | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Syrup | ORCIPRENALINE SULFATE 10 MG | Cancelled Post Market |
| 00003891 | ALUPENT TAB 20MG | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Tablet | ORCIPRENALINE SULFATE 20 MG | Cancelled Post Market |
| 02229862 | ORCIPREN | TECHNILAB PHARMA INC. | Syrup | ORCIPRENALINE SULFATE 10 MG | Cancelled Post Market |
| 02236783 | ORCIPRENALINE | AA PHARMA INC | Syrup | ORCIPRENALINE SULFATE 2 MG | Dormant |
| 02152568 | RATIO-ORCIPRENALINE SYRUP 2MG/ML | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Syrup | ORCIPRENALINE SULFATE 2 MG | Cancelled Post Market |
| 02192675 | TANTA ORCIPRENALINE SYRUP - SYR 2MG/ML | TANTA PHARMACEUTICALS INC | Syrup | ORCIPRENALINE SULFATE 2 MG | Cancelled Post Market |
International API supply for ORCIPRENALINE SULFATE
1 valid EDQM Certificates of Suitability from 1 holders.
Request a quote for ALUPENT LIQ 50MG/ML